CHChloe Hutchins

Chloe Hutchins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chloe Hutchins has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pragmatic water and health research in a complex emergency: Learnings and way forward

    by Karin Gallandat, Jaime Mufitini Saidi, Baron Bashige Rumedeka, Damien Machuel, Audrey Seon, Espoir Bwenge Malembaka, Patrick Musole Bugeme, Esther German, Didier Bompangue, Chloe Hutchins, et al.

    Climate change is straining water and sanitation services (WSS), leading to disruptions that threaten public health. In low-income and fragile contexts, there is an urgent need to increase investments in WSS, as well as to enhance efficiency in the utilisation of available financial resources. Operational research can help optimise future investments in WSS. In this perspective, we share our experience carrying out research embedded within a large-scale water supply infrastructure improvement programme in an urban, cholera-endemic area in South Kivu (Democratic Republic of the Congo). Through the lens of this concrete example, we highlight the need for rigorous research on higher quality drinking water services in low-income and fragile countries, discuss how multi-stakeholder research partnerships and pragmatic methods can contribute to the generation of rigorous evidence where it is most needed, and illustrate the role of research in strengthening capacities for both science and practice.

  • Open Access

    Impact of mass oral cholera vaccination in an endemic area of the Democratic Republic of the Congo: a surveillance-based counterfactual modeling analysis

    by Javier Perez-Saez, Espoir Bwenge Malembaka, Judith A Bouman, Patrick Musole Bugeme, Chloe Hutchins, Jules Jackson, Esperance Tshiwedi-Tsilabia, Juan Dent Hulse, Jaime Mufitini Saidi, Baron Bashige Rumedeka, et al.

    Background: Oral cholera vaccines (OCVs) are a key component of cholera control recommended in cholera-endemic areas. Yet evidence of their population-level impact is limited, especially in Africa where most cholera deaths occur. Here, we estimate the impact of mass administration of OCVs in the cholera-endemic city of Uvira, Democratic Republic of the Congo. Methods: We conducted enhanced cholera surveillance at the two official cholera treatment facilities in Uvira between Jan 2017 and Dec 2023, centered around a mass vaccination campaign that achieved 66% coverage with at least one dose of Euvichol Plus vaccine in 2020. We combined systematic rapid diagnostic case testing with repeated, representative population surveys capturing healthcare-seeking behavior, vaccination, population mobility, and antibody profiles to estimate seroincidence. We developed a Bayesian framework that integrates these data into an ensemble of mechanistic cholera transmission models that account for time-varying transmissibility, realistic immunity dynamics and loss of vaccination coverage to population turnover. OCV impact was assessed through ensemble counterfactual modeling of alternative vaccination scenarios. Findings: We estimate that the 2020 mass vaccination averted 56% (95% Credible Interval: 34-81) of infections and deaths over the subsequent three years. This corresponds to 2,350 (median, 95% CrI: 890-8,960) averted facility-attended cases, and 44 (median, 95% CrI: 16-150) averted facility and community deaths. Vaccination of all of Uvira’s eligible population would have averted 64% (median, 95% CrI: 43-87) of cases and deaths, with a negative but limited influence of vaccine coverage loss because of population turnover (71% median, 95% CrI: 52-90 at half the population turnover). Interpretation: Although mass vaccination averted a significant fraction of cholera cases that would have otherwise occurred in this endemic setting, imperfect coverage, population turnover, and high transmission rates contributed in offsetting the larger potential benefits of OCV. Successful cholera control in Uvira hinges on multisectorial approaches including provision of safe water and sanitation. Setting and communicating realistic expectations for mass vaccination programs in highly endemic areas is critical for maintaining confidence in the current generation of OCVs. Funding: Gavi (M&E 9166 09 20 A16) and the Wellcome Trust (221688/Z/20/Z). Research in Context: Evidence before this study: We searched PubMed for studies published between January 1, 2000 and June 2026 using the terms (“oral cholera vaccine” OR “OCV”) AND (“vaccine effectiveness” OR “vaccine impact” OR “indirect protection” OR “herd immunity” OR “population-level protection”). We also reviewed World Health Organisation (WHO) position papers and reports from the Global Task Force on Cholera Control (GTFCC). Inactivated oral cholera vaccines provide strong direct protection against symptomatic cholera, with randomized controlled trials and observational studies reporting effectiveness estimates typically exceeding 50% in the first three years after vaccination. In a previous study we showed that one-dose vaccine effectiveness was 52% 12-17 months after vaccination in Uvira, DRC. However, evidence on the population-level impact of preventive mass vaccination campaigns, which encompasses both direct and indirect protection, is thin. The only published estimates from clinical trials, both conducted in South Asia, reported overall protection of 37% over a 2-year period in Dhaka, Bangladesh and 75% over a 3-year period in Kolkata, India. No rigorous real-world estimates of mass OCV impact have been published from sub-Saharan Africa, where the vast majority of global cholera deaths occur. A major obstacle behind this gap is the lack of high-quality pre- and post-vaccination surveillance to support robust estimation of impact. The WHO and GTFCC have identified this evidence gap as a major research priority. Added value of this study: To our knowledge, this is the first study to provide a rigorous, data-driven estimate of the population-level impact of a preventive mass OCV campaign in a cholera-endemic African setting. Drawing on 7 years of enhanced clinical surveillance, three population-representative household surveys measuring vaccine coverage, population mobility and health-care seeking behaviors, a serological survey, and a novel ensemble of compartmental transmission models, we estimated that the 2020 campaign in Uvira, DRC — which achieved approximately 66% coverage of at least one dose of Euvichol Plus vaccine — averted 56% (95% CrI: 34-81) of cholera cases and deaths over the subsequent three years. This corresponds to 2,350 (median, 95% CrI: 890-8,960) averted cases that would have sought care at official cholera treatment facilities, and 44 (median, 95% CrI: 16-150) averted deaths. Our transmission modeling framework also yielded new insights into cholera natural history in this endemic setting: symptomatic infection conferred strong and durable immunity (mean duration 6 years), while immunity following asymptomatic infection was substantially weaker. We further quantify how vaccination coverage and population turnover jointly determine vaccination program impact, providing a practical framework for informing future campaign design. Implications of all the available evidence: Taken together with prior evidence from South Asia, our findings indicate that preventive mass OCV campaigns can avert a substantial fraction of cholera cases and deaths in highly endemic settings across different epidemiological contexts. Nonetheless, the resurgence of cholera a year after the vaccination campaign underscores that OCV campaigns alone are insufficient for sustained cholera control in similar settings due to high transmission rates and high population...

  • Open Access

    Temporal dynamics of SARS-CoV-2 shedding in feces and saliva: a longitudinal study in Norfolk, United Kingdom during the 2021–2022 COVID-19 waves

    by Lee Kellingray, George M. Savva, Enriqueta Garcia-Gutierrez, Jemma Snell, Stefano Romano, Daniel Alejandro Yara, Annalisa Altera, Leonardo de Oliveira Martins, Chloe Hutchins, David Baker, et al.

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was originally described as a respiratory illness; however, it is now known that the infection can spread to the gastrointestinal tract, leading to shedding in feces potentially being a source of infection through wastewater. We aimed to assess the prevalence and persistence of SARS-CoV-2 in fecal and saliva samples for up to 7 weeks post-detection in a cohort of 98 participants from Norfolk, United Kingdom using RT-qPCR. Secondary goals included sequencing the viral isolates present in fecal samples and comparing the genetic sequence with isolates in the saliva of the same participant. Furthermore, we sought to identify factors associated with the presence of detectable virus in feces or saliva after a positive SARS-CoV-2 test. Saliva remained SARS-CoV-2-positive for longer periods compared to fecal samples, with all positive fecal samples occurring within 4 weeks of the initial positive test. Detectable virus in fecal samples was positively associated with the number of symptoms experienced by the individuals. Based on the genome sequencing and taxonomic classification of the virus, one donor had a distinct strain in feces compared to saliva on the same collection date, which suggests that different isolates could dominate different tissues. Our results underscore the importance of considering multiple biological samples, such as feces, in the detection and characterization of SARS-CoV-2, particularly in clinical procedures involving patient fecal material transplant. Such insights could contribute to enhancing the safety protocols surrounding the handling of patient samples and aid in devising effective strategies for mitigating the spread of coronavirus disease. IMPORTANCE: This study provides critical insights into the dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) shedding in fecal and saliva samples, demonstrating that while viral RNA is detectable shortly after diagnosis, its prevalence declines rapidly over the course of infection. Detection was more common among individuals with more concurrent symptoms, emphasizing the potential influence of symptom burden on viral persistence. By analyzing a United Kingdom-based cohort, this study fills a significant gap in the literature, which has largely focused on Asian and North American populations, offering a geographically unique perspective on viral shedding dynamics. Our findings contribute to a globally relevant understanding of SARS-CoV-2 shedding by revealing differences in shedding durations compared to studies from other regions. These differences highlight the need for geographically diverse research to account for variations in genetic background, immune response, and healthcare practices.


  • Open Access

    Cholera Deaths During Outbreaks in Uvira, Eastern Democratic Republic of the Congo, 10–35 Months After Mass Vaccination

    by Patrick Musole Bugeme, Hanmeng Xu, Chloe Hutchins, Juan Dent, Jaime Mufitini Saidi, Baron Bashige Rumedeka, Moïse Itongwa, Joël Faraja Zigashane Mashauri, Faraja Masembe Lulela, Justin Bengehya, et al.

    Our understanding of the burden and drivers of cholera mortality is hampered by limited surveillance and confirmation capacity. Leveraging enhanced clinical and laboratory surveillance in the cholera-endemic community of Uvira, eastern Democratic Republic of Congo, we describe cholera deaths across 3 epidemics between September 2021 and September 2023 following mass vaccination.


  • Open Access

    Effectiveness of one dose of killed oral cholera vaccine in an endemic community in the Democratic Republic of the Congo: A matched case-control study

    by Espoir Bwenge Malembaka, Patrick Musole Bugeme, Chloe Hutchins, Hanmeng Xu, Juan Dent Hulse, Maya N. Demby, Karin Gallandat, Jaime Mufitini Saidi, Baron Bashige Rumedeka, Moïse Itongwa, et al.

    Background: A global shortage of cholera vaccines has increased the use of single-dose regimens, rather than the standard two-dose regimen. There is limited evidence on single-dose protection, particularly in children. In 2020, a mass vaccination campaign resulting in largely single dose coverage, was conducted in Uvira, an endemic urban setting in eastern Democratic Republic of the Congo. We examined the effectiveness of a single-dose of the oral cholera vaccine Euvichol-Plus ® in this high-burden setting. Methods: We recruited medically attended confirmed cholera cases and age-, sex-, and neighborhood-matched community controls during two distinct periods after mass vaccination, October 2021 to March 2022 (12–17 months post-vaccination) and October 2022 to October 2023 (24–36 months post-vaccination). The odds of vaccination in cases and controls were contrasted in conditional logistic regression models to estimate unadjusted and adjusted vaccine effectiveness. Findings: We enrolled 658 confirmed cases and 2,274 matched controls during the two study periods with 15·0% of cases being under five years old at the time of vaccination. The adjusted single-dose VE was 52·7% (95% CI: 31·4–67·4) 12–17 months post-vaccination and 45·5% (95% CI: 25·8– 60·0) 24–36 months post-vaccination. While protection in the first 12–17 months post-vaccination was similar for 1–4-year-olds and older individuals, over the third year post-vaccination the estimate of protection in 1–4 year-olds (adjusted VE 33·1%; 95% CI: -30·0–65·6) appeared to wane with confidence intervals spanning the null. Interpretation: A single-dose of Euvichol-Plus ® provided substantial protection against medically attended cholera for at least 36 months post-vaccination in this cholera endemic setting. While our evidence provides support for comparable levels of protection in young children and others in the short-term, protection among young children may wane significantly by the third year after vaccination. Funding: Wellcome Trust and Gavi (GAVI-RFP-2019-062). Research in context: Evidence before this study: In late 2022, due to increasing demand for killed, whole-cell, oral cholera vaccines (kOCV) and limited production capacity, the International Coordinating Group (the organization managing emergency stocks of kOCVs) changed policy to deploy single-dose, rather than the standard two-dose regimen, for emergency vaccination campaigns. This decision was in line with WHO guidance on the use of a single dose in outbreaks, where short-term protection is key. However, this recommendation is based on a limited number of clinical studies with short-term follow-up. There is also limited evidence on the magnitude and duration of protection conferred by a single dose of kOCV, particularly in children under five years of age. We searched PubMed for randomized trials and observational studies published in English before November 1, 2023, that reported estimates of protection conferred by a single dose of kOCV, using the term “(effectiveness OR efficacy) AND cholera* AND vaccine”. We found no published studies estimating the effectiveness of a single dose of Euvichol-Plus ® , and only one study reporting two-dose effectiveness. Despite this paucity of evidence, this is the only vaccine currently available in the global stockpile. To date, there has been one randomized trial conducted in Bangladesh between 2014 and 2016, and seven observational studies conducted between 2009 and 2016 in Guinea, Haiti, India, Malawi, Sudan, Zambia and Zanzibar, reporting effectiveness estimates of a single dose of the current generation of kOCV. Aside from the trial in Bangladesh, all estimates were based on secondary analyses that the studies were not powered to estimate. The Bangladesh trial is the only study to date that provides an age-stratified estimate of single-dose protection, and while it found an overall protective efficacy of 62% (95% CI: 43– 75) during the 2-year follow up for individuals aged five years or older, it found no significant protection conferred by the Shanchol kOCV (a bioequivalent of Euvichol-Plus ® ) for individuals under five years of age (protective efficacy: -44%, 95% CI -220 to 35). Four of the seven observational studies provide single-dose vaccine effectiveness (VE) estimates only during the first 12 months post-vaccination with estimates ranging from 43% (95% CI -84-82) in Guinea to 93% (95% CI 69-98) in Haiti. The three other observational studies providing a single dose VE estimate between 12-30 months post-vaccination were unable to demonstrate statistically significant protection conferred by kOCV, with estimates ranging between 32·5% (95% CI - 318·0-89·1) in India and 40% (95% CI -31-73) in Haiti. No vaccine protection estimates have been published from the two identified cholera endemic foci in Africa, the Democratic Republic of the Congo and Nigeria. Added value of this study: In this vaccine effectiveness study, we show that a single dose of Euvichol-Plus ® vaccine can provide significant protection against medically attended cholera for up to 36 months after vaccination in a cholera endemic setting in Africa, though protection in children under five years old remains unclear. These estimates help fill critical gaps in our understanding of the magnitude and duration of protection from a single dose of the most widely used kOCV, Euvichol-Plus ® and is one of only a few studies to measure protection in an endemic setting in Africa. Implications of all the available evidence: The corpus of available evidence suggests that use of a single dose of kOCV in emergency situations where cholera is endemic, like Uvira, is justified and that providing a second dose within the first 12-24 months post-vaccination may only provide marginal benefit to the general population. However, more evidence and analyses are needed to weigh the costs and benefits of tailored vaccination approaches for those under five years old, including possibility of providing a second dose at an earlier timepoint.

  • Open Access

    An optimised protocol for detection of SARS-CoV-2 in stool

    by T Li, E Garcia-Gutierrez, J Scadden, J Davies, C Hutchins, A Aydin, S Romano, L Sayavedra, J O’grady, A Narbad

    Aim SARS-CoV-2 has been detected in stool samples of COVID-19 patients, with potential implications for faecal-oral transmission. Compared to swab samples, the complexity of the stool matrix poses a challenge in the detection of the virus that has not yet been solved. The aim of this study was to establish a sensitive and reliable method for detecting SARS-CoV-2 in stool samples. Methods Stool samples from individuals free of SARS-CoV-2 were homogenised in saline buffer and spiked with a known titre of inactivated virus ranging from 50 to 750 viral particles per 100 mg stool. Debris was removed via centrifugation and supernatants were concentrated by ultrafiltration. RNA was then extracted from the concentrated material using a commercial kit and SARS-CoV-2 was detected via real-time reverse-transcription polymerase chain reaction (RT-qPCR) using the CDC primers and probes. Results The RNA extraction procedure we used allowed the detection of SARS-CoV-2 via RT-qPCR in most of the stool samples tested. We could detect as few as 50 viral particles per 100 mg of stool. However, high variability was observed across samples at low viral titres. The primer set targeting the N1 region provided more reliable and precise results and for this primer set our method had a limit of detection of 1 viral particle per mg of stool. Conclusions Here we describe a sensitive method for detecting SARS-CoV-2 in stool samples. This method can be used to establish the persistence of SARS-CoV-2 in stool and ensure the safety of clinical practices such as faecal microbiota transplant (FMT).